




SPONSORED BY THE



Federal Ministry  
of Education  
and Research

# Parlamentarisches Frühstück der PDP Koalition





# DER TRAUM DES PROFESSORS ASSANI






## **BEST SCIENCE FOR THE MOST NEGLECTED**



We **discover, develop,**  
and accelerate **access**  
to urgently needed **treatments** for  
neglected patients  
focusing on **gaps** for infectious  
diseases that fuel cycles of poverty and  
disease in resource-constrained settings

# 25 treatments in 25 years



Deliver **15 - 18 treatments from 2021 - 2028\***  
for a total of **25 treatments in our first 25 years\*\***



**10 - 12 new treatments**  
from current mature portfolio (2021-24)



**5 - 7 new treatments**  
from earlier-stage NCEs and portfolio expansion (2025-28)

\*4 delivered so far

\*\*12 delivered so far

## OTHER STRATEGIC IMPERATIVES:



**2** Place public health leaders and R&D actors in low- and middle-income countries at the center of DNDi collaborations for inclusive and sustainable solutions



**3** Contribute to building a proactive agenda for child health and gender-responsive R&D



**4** Champion open science and transparency



**5** Leverage new technologies and new therapeutic modalities to accelerate R&D and access

# INNOVATING TO SAVE LIVES

With BMBF's support we will discover and develop...

...adapted, affordable and accessible treatments

...with patients and public health systems needs in mind.

**DNDi**



## Sleeping sickness

Accelerate sustainable disease elimination



## Leishmaniasis

Deliver safer, simpler treatments to save lives and reduce social stigma



## Chagas disease

Contribute to eliminating Chagas as a public health problem




## Filaria (river blindness)

Advance progress toward breaking the cycle of transmission



## Mycetoma

Prevent devastating amputation and disability



## Dengue

Accelerate R&D to address the most prevalent mosquito-borne viral disease



## HIV

Ensure access to life-saving treatment for children and people with advanced HIV



## Hepatitis C

Help make treatment a reality for millions of people waiting for a cure



## COVID-19/ pandemic-prone diseases

Speed tools to save lives, especially in resource-limited settings



## New areas to be explored:

Schistosomiasis, snakebite, rabies



# RIVER BLINDNESS

DEVELOPING A RAPID CURE FOR MILLIONS AT RISK  
OF THE 2<sup>nd</sup> LEADING INFECTIOUS CAUSE OF BLINDNESS

## FACTS

**About 240 million**  
people at risk

**19 million**  
people  
infected

**>1 million**  
people with  
vision loss

## CHALLENGES

Available drug reduces transmission but **only kills juvenile worms**, so must be administered every year **for 10 years or more**.

New tools needed to tackle **elimination challenges** and provide **drugs for individual care**.

## OUR WORK

We have built a **portfolio of four R&D projects** and are advancing development of potential **new drug candidates** with our partners.

## OUR GOALS

**2021-2028: Advance progress toward breaking the cycle of transmission**


- Conduct Phase II trials to **identify one or a combination of new drug candidates**
- Launch **Phase III confirmatory trial** that we hope will result in a new treatment
- Support the development of **urgently needed diagnostic tools**

**MAIN PARTNERS:** AbbVie, Bayer, Elanco, Erasmus Medical Center, Ifakara Health Inst., Imperial College, IRD - France, LSHTM, Mahidol Oxford Tropical Medicine Inst., Museum National d'Histoire Naturelle - Paris, REFOTDE - Cameroon, Swiss TPH, University Of Health And Allied Sciences Ghana, University Hospital Bonn, Washington University St Louis






# Collaboration is an essential part of DNDi's model



## A WORLDWIDE FOOTPRINT, WITH CLOSE TO 60% OF PARTNERS IN LMICS


Partners by region



- East & Asia Pacific
- Europe & Central Asia
- Latin America & Caribbean
- Middle East & North Africa
- North America
- South Asia
- Sub-Saharan Africa

## A DIVERSE RANGE OF ALLIANCES

Partners by type



- Industry partners
- Universities and research centres
- Ministries of health and governments
- Non-profit organizations, NGOs, and networks
- Healthcare providers



**Danke!**

**Laurent Fraisse, R&D Director**

**lfraisse@dndi.org**

 [facebook.com/dndi.org](https://facebook.com/dndi.org)  
 [youtube.com/dndiconnect](https://youtube.com/dndiconnect)  
 [twitter.com/dndi](https://twitter.com/dndi)

 [instagram.com/drugsforneglecteddiseasesinitiative](https://instagram.com/drugsforneglecteddiseasesinitiative)  
 [linkedin.com/company/dndi](https://linkedin.com/company/dndi)

**DNDi**  
Best Science  
for the Most Neglected 